Genetesis develops the CardioFlux biomagnetic imaging platform that leverages magnetocardiography to provide rapid, noninvasive cardiac assessments without radiation, contrast, or exercise. CardioFlux was cleared by the FDA in 2019 and received FDA Breakthrough Device designation in December 2020. The system has been clinically investigated in hundreds of patients with suspected acute and chronic coronary syndromes and in patients with confirmed coronary microvascular dysfunction. Genetesis is completing primary enrollment in the ACCMED trial with participating centers including Cleveland Clinic, Ascension St. John, Wake Forest Baptist Health, and Beaumont Royal Oak Hospital. The company plans to use recent financing to obtain FDA De Novo approval, launch additional clinical trials, and commercialize its biomagnetic systems globally across a variety of care settings. Following the Series C close, total funding exceeds $40 million. Genetesis has developed the CardioFlux Magnetocardiograph (MCG) for chest pain, addressing a problem that causes eight million emergency department visits annually. CardioFlux enables physicians to measure and record the heart's magnetic fields in a few minutes. The system operates without ionizing radiation, without exercise protocols, and without the need for specialized room modifications. The technology has the potential to lower emergency department length of stay for chest pain patients. Financially, the company raised $9.2M in Series B financing that included strategic investments from TDK Ventures and an undisclosed Fortune 500 global healthcare company, alongside return investors CincyTech, Ohio Innovation Fund and Mark Cuban. The company also added Sajid Malhotra to its board. Genetesis develops biomagnetic imaging systems and proprietary software to detect ischemic cardiac tissue and enable rapid, noninvasive chest pain triage. Its CardioFlux system performs a passive 60–90 second scan with no radiation or exercise required. The company completed a 100-patient, double‑blinded clinical study at St. John Hospital and described the findings as encouraging, with plans to publish in peer‑reviewed journals. Genetesis aims to give clinicians an accurate, easy‑to‑operate tool that can reduce the need for invasive and lengthy testing. The company plans to build and install additional CardioFlux systems, launch new clinical trials, and prepare for commercial launch. Genetesis is based in Mason, Ohio and will preview its technology at the American College of Emergency Physicians and American Heart Association Scientific Sessions. Genetesis develops CardioFlux™, a medical device that provides accurate, noninvasive 3D mapping of the heart's electrical activity. The system is intended to diagnose, characterize, and guide treatment for myocardial ischemia, atrial fibrillation, ventricular tachycardia and other arrhythmias, offering more insight than a conventional ECG. The company presented data collected with the Mayo Clinic at the American Heart Association Scientific Sessions showing promising improvements in noninvasive detection of ischemia in high‑risk chest pain compared with existing ER tools. Genetesis was founded in Mason, Ohio in 2013 and now employs a team of ten. The company plans to use the funding to scale engineering, launch additional clinical studies, and seek FDA regulatory clearance. Investors and management also see potential to expand the CardioFlux platform beyond cardiac applications into markets such as magnetic brain imaging.

Total raised

$35M

Funding rounds

4

Latest round

Series C

Latest activity

Oct 2022